We read with interest the Article by Eva Morris and colleagues,
- published in The Lancet Gastroenterology & Hepatology, and welcome the valid concerns raised. Analysis of population-based data has provided a rapid insight into the effect of COVID-19 on referral and management of patients with colorectal cancer in England during the first wave of the pandemic and the subsequent recovery period. This study documents changes made to investigative and treatment pathways in response to national guidance in the UK
- and the subsequently reduced capacity to investigate patients presenting with bowel symptoms.